Key Takeaways
- H1 revenue muted, H2 must deliver the year: H1 grew only ~5% as instrument orders stalled, but management is "very confident" on the full-year ₹400 crore target, implying a back-half surge to hit the 25–30% growth guide.
- The reagent engine is the real story: Reagent sales hit 71% of revenue, up from 63%, lifting gross margin to 62.2%. Instruments are low-margin drivers for a reagent business that earns 3x–4x profit, and management calls reagents "the only area of interest."
- Unit 4 is the swing factor: The new plant's product licenses jumped from 9 to nearly 36, and monthly kit production is set to quadruple to 35,000–40,000. At least ₹150–160 crore of FY27 revenue is pegged to this one facility.
- A deliberate shift away from government: Management is consciously moving the mix from 60:40 government-private toward 40:60 by March '27 and under 30–40% by March '28, aiming to fix receivables and cash flow.
- What to watch next quarter: Whether Unit 4's production ramp actually hits the 35,000–40,000 kit/month run rate, the pace of government order execution in H2, and any resolution of the UP consignment list that management says could make growth "manifold."
The H2 Bet: Why a ~5% H1 Must Become 25–30% Full-Year
- H1 was held back by instrument delays, not demand destruction: Instrument revenue fell 29% because certain government orders could not be executed on time due to non-availability of consignee, while the trade and reagent businesses both grew ~20%.
- H2 is structurally bigger in diagnostics: Management notes H2 always contributes 60–70% of full-year revenue, and this year new product launches are concentrated in the second half, so the skew is even sharper.
- The ₹400 crore confidence is absolute: Management stated "we are not doubt about it" on hitting the full-year target, with the reagent business providing consistent month-on-month volume and government budgets typically improving later in the year.
- FY28 is already penciled at the same pace: Management would like to maintain 25–30% growth for FY28 as well, driven by products being developed in FY27, continued new product development, and SKD instrument expansion.
- The risk is execution, not ambition: The UP project with more than 1,000 consignees remains delayed, and an election year in the state creates an adverse situation; management is trying to secure the consignment list and has alternative plans if it does not materialize.
Meenal Gupta: "Looking at also that our H2 is always better, so I think we do see 25 to 30% growth for the year, for the year, YOY."
Unit 4: The Production Ramp That Carries the Model
- Licenses are the gate, and the gate is opening: Product licenses rose from 9 as of 30 September to almost 36 now, out of more than 130 planned; additional licenses are under various stages of approval, with third-party testing at ICMR and NIB in progress.
- Production is set to quadruple this month: The facility has been manufacturing 5–6 products for ~4 months at 8,000–10,000 kits/month; from this month, ~30 additional products enter production, taking output to 35,000–40,000 kits/month.
- FY27 revenue commitment is specific: At least ₹150–160 crore of business will be generated from Unit 4 (C42) in FY27, with capacity utilization expected to reach 25–30% by 27 March.
- FY28 ambition scales further: Management sees >₹120 crore minimum from Unit 4 in FY28, rising to ₹250–300 crore if Class C and D licenses are received, with ~₹250 crore of reagent revenue shifting from old plants to Unit 4.
- The facility unlocks institutional and international opportunities: Unit 4 strengthens in-house manufacturing, expands the product range, and provides infrastructure for larger tenders and export orders that the older plants could not support.
Ajay Kumar Mahanty: "More than 150 to 160, 150 crore rupees business at least we'll generate from C42."
Reagents: The Profit Engine and Strategic Center
- The mix shift is structural and margin-accretive: Reagent sales rose to 71% of total revenue in H1 FY27 from 63% in H1 FY26, driving gross margin improvement from 57.7% to 62.2%.
- Instruments earn 5–10%, reagents earn 3x–4x: Management is explicit that instruments are low-margin drivers placed to seed the recurring, high-profit reagent stream; the strategy is to place instruments with reagent commitment contracts of ~₹2 lakh/month per account.
- Reagents are consistent, instruments are lumpy: The reagent business shows consistency every month and every year, while instrument revenue is subject to government budget cycles and consignee availability, making the reagent shift a volatility reducer.
- Long-term target is 65–70% reagent share: Management sees this as the ideal industry structure and the path to sustainability and profitability, with the transition happening over approximately five years.
- In-house raw material development adds another margin lever: Four clinical chemistry raw materials have been developed in-house and put into use, reducing import dependence and cost.
Ajay Kumar Mahanty: "Our area of interest, that is not the instrument sale. Our area of interest basically is the reagent cell."
The Government-to-Private Pivot
- The current mix is a working-capital drag: Government sales are ~60% of revenue with a 4–5 month receivable cycle, and orders require complete supply with shelf-life conditions before the cycle even starts, keeping receivables high as a percentage of the top line.
- The target trajectory is explicit: 40:60 government-to-private by March '27, then less than 30–40% government by March '28, and around 30:70 from an FY29 perspective, moving gradually.
- Growth will come from non-government channels: Management is adding instruments for placement in bigger lab chains and key accounts like Dr. Lal, expanding trade sales (up 20% in H1), and building export and CDMO revenue streams that take advance payments.
- POCT is being wound down as a channel, not as a revenue stream: The percentage of revenue from POCT decreased from 65–70% to 55–60% as the company shifts to direct Q-Line billing to government and increases trade sales; related-party transactions ease out as a result.
- The working-capital payoff is material: Management expects ~30 days of improvement by FY27 end, with standard 2–3 months (60–90 days) as CDMO, export, and private sales scale during FY28, plus interest cost savings of ₹4–5 crore in H2 from IPO-fund loan repayment.
Meenal Gupta: "So slowly, I think by the time- so we are almost at a 50-50% ratio right now, but I think when we reach March '27, it will be a 40-60%... And as we go into March '28, we are looking at further decreasing the government part of our business. It will be less than 30 to 40%, and these are the initiatives that, you know, consciously the management is making these steps to slightly move away from the government business so that the overall cash flow of the company can be improved."
New Product Pipeline and CDMO
- Chemiluminescence is the next big segment entry: NOD has been received from CDSCO for more than 25–30 products; instrument approvals are awaited, and management hopes to launch in the last quarter of FY27.
- Molecular diagnostics is scaling fast: Hepatitis B, hepatitis C, HIV, and Triple H detection kits have been launched, along with an integrated 3-in-1 blood bank screening test; quantitative molecular kits for patient monitoring are commercialized; management says the molecular basket "is going to be very big very soon" with 25–30 parameters, a respiratory panel, a TB solution, and cancer markers in development.
- CDMO is moving from concept to commercial: A €2.3 million import order has been received from a European principal for Selectra Pro M and Microlab 300; commercial sales of MicroLab began in October; one Netherlands CDMO project is ongoing and will serve 55–60 countries; another CDMO project for a new model is about to be signed.
- CDMO instruments carry 25–30% gross margin: Management expects healthy profitability on these export instruments, and advance payment terms (at least 50% upfront) improve cash flow.
- SKD instruments add domestic and export volume: Q-Count 3 and Q-Count 5 hematology analyzers launched on SKD basis and sold in trade sales in H1; Q-Count 5 autoloader to launch probably in November; Medonic 3-part from Sweden to begin manufacturing in a few weeks.
- Export registrations are building a foundation: Products are registered in more than 10–11 countries with distributors appointed; registration completed for Egypt and other countries; over ₹0.23 crore of export orders already received, though geopolitical conditions in West Asia may cause near-term delays to the fivefold export growth target.
Margins, Profitability, and the Hidalgo Consolidation
- EBITDA grew 10% despite a margin dip: H1 EBITDA margin was 26%, down from the ~28% FY26 full-year target, because Unit 4 capitalization in Q4 FY26 added depreciation of ₹7.89 crore (up from ₹4.09 crore) and operational expenses.
- PAT moderation is non-operational: PAT fell to ₹19.60 crore from ₹21.32 crore entirely because of higher depreciation and the absence of a one-time tax writeback of ₹1.95 crore recorded in H1 FY26; management believes both EBITDA and PAT targets will be achieved for the full year.
- FY27 EBITDA margin target is ~28%: Currently at 26% in H1, management expects to recover to the FY26 level as Unit 4 production scales and operating leverage kicks in.
- Hidalgo Medical doubles revenue, adds a new vertical: Revenue grew from ~₹51 crore to ~₹108 crore, PAT from ₹3 crore to ₹7.9 crore; the products are entirely different from Q-Line (critical care/ICU vs IVD blood testing); FY27 guidance is ~₹130 crore top line, with margins expected to improve as Hidalgo moves from SKD into manufacturing.
- Interest cost savings are back-loaded: IPO funds were used to repay loans in June and July with foreclosure charges, so the benefit was not fully reflected in H1; H2 will show a clear saving of ₹4–5 crore.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year FY27 revenue | ₹400 crore (25–30% YoY growth) | FY27 |
| FY28 revenue growth | Maintain 25–30% growth | FY28 |
| Unit 4 (C42) revenue | At least ₹150–160 crore | FY27 |
| Unit 4 capacity utilization | 25–30% | By 27 March FY27 |
| Unit 4 monthly kit production | 35,000–40,000 kits/month | From this month (Q3 FY27) |
| Unit 4 revenue (FY28) | >₹120 crore minimum; ₹250–300 crore if Class C & D licenses received | FY28 |
| Government-to-private mix | 40:60 | By March '27 |
| Government-to-private mix | <30–40% government | By March '28 |
| Government-to-private mix | ~30:70 | FY29 perspective |
| FY27 EBITDA margin | ~28% (same as FY26) | FY27 |
| Hidalgo Medical revenue | ~₹130 crore | FY27 |
| Working capital improvement | ~30 days improvement | By FY27 end |
| Working capital normalization | 60–90 days (2–3 months) | During FY28 |
| Chemiluminescence launch | Commercial launch | Last quarter FY27 |
| Reagent revenue share | 65–70% of total revenue | Long-term (~5 years) |
| Interest cost saving | ₹4–5 crore | H2 FY27 |
Key Metrics
| Metric | H1 FY27 |
|---|---|
| Revenue from operations | ₹152 crore, +5.83% YoY |
| EBITDA | ₹39.57 crore, +10.02% YoY |
| EBITDA margin | 26.0%, improved 99 bps YoY from 25.1% |
| Gross margin | 62.2%, up from 57.7% in H1 FY26 |
| Profit after tax | ₹19.60 crore, down from ₹21.32 crore in H1 FY26 |
| Depreciation | ₹7.89 crore, up from ₹4.09 crore in H1 FY26; Unit 4 capitalization impact |
| Reagent business growth | 19.23% YoY |
| Trade market business growth | ~20.13% YoY |
| Instrument revenue change | -29% YoY; government order execution delayed |
| Reagent share of total sales | 71%, up from 63% in H1 FY26 |
| Product licenses at Unit 4 | 36, up from 9 as of 30 September |
| CDMO import order value | €2.3 million, combined for Selectra Pro M and Microlab 300 |
| Hidalgo Medical FY26 revenue | ~₹108 crore, up from ₹50.91 crore in 2024 |
| Hidalgo Medical acquisition value | ~₹26.93 crore for 70% stake |
| Government share of total sales | ~60%; receivable cycle 4–5 months |
| Installed instrument base | ~16,000 instruments; hematology ~8,000–9,000, fully auto ~3,000 |